Azala

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL): Matching Adjusted Indirect Comparisons (MAICs) and Systematic Review

Despite favorable results of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), several challenges remain, including incomplete response, immune-mediated toxicity, and antigen-loss relapse. We delineated the relative clinical benefit of the novel approaches compared to the...

Deskribapen osoa

Gorde:

Xehetasun bibliografikoak
Egile Nagusiak:	Bayarmagnai Weinstein (Egilea), Bogdan Muresan (Egilea), Sara Solano (Egilea), Antonio Vaz de Macedo (Egilea), YoonJung Lee (Egilea), Yu-Chen Su (Egilea), Yeseul Ahn (Egilea), Gabriela Henriquez (Egilea), Christina Carmago (Egilea), Gwang-Jin Kim (Egilea), David O. Carpenter (Egilea)
Formatua:	Liburua
Argitaratua:	University of Minnesota Libraries Publishing, 2021-11-01T00:00:00Z.
Gaiak:	article
Sarrera elektronikoa:	Connect to this object online.
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
nork: Jain MD, et al.
Argitaratua: (2018)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma
nork: Maria Giraudo, et al.
Argitaratua: (2024)

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
nork: Hamed Dabiri, et al.
Argitaratua: (2023)

Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
nork: Javad Masoumi, et al.
Argitaratua: (2021)

Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T
nork: Aman P. Singh, et al.
Argitaratua: (2021)

Chimeric miRNA cluster enables multiplex and titratable gene inhibition in CAR-T cells
nork: Reka Agnes Haraszti
Argitaratua: (2023)

Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy
nork: Beatrice Spokeviciute, et al.
Argitaratua: (2024)

Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
nork: Qibin Liao, et al.
Argitaratua: (2020)

The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors
nork: Kaveh Hadiloo, et al.
Argitaratua: (2023)

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)
nork: Kathryn Kline, et al.
Argitaratua: (2023)

Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023
nork: Wangshu Li, et al.
Argitaratua: (2024)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
nork: Zakaria Grada, et al.
Argitaratua: (2013)

Relevant nursing measures for the adverse reactions associated with chimeric antigen receptor T cells (CAR-T) immunotherapy: a systematic review of case reports†
nork: Zhang Xu, et al.
Argitaratua: (2019)

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
nork: Johannes Kast, et al.
Argitaratua: (2022)

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo
nork: Qibin Liao, et al.
Argitaratua: (2020)

Engineering CAR-T cells
nork: Cheng Zhang, et al.
Argitaratua: (2017)

Chimeric RNA in Cancer and Stem Cell Differentiation
nork: Justin Elfman, et al.
Argitaratua: (2018)

Donor T cells for CAR T cell therapy
nork: Tiffany C. Y. Tang, et al.
Argitaratua: (2022)

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis
nork: James Signorovitch, et al.
Argitaratua: (2023)

Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
nork: Alejandrina Hernández-López, et al.
Argitaratua: (2021)

Chimeric maternal cells as T lymphocyte targets in pediatric SLE
nork: Stevens Anne M, et al.
Argitaratua: (2012)

Chimeric antigen receptor T cell therapy for multiple myeloma
nork: Kana Hasegawa, et al.
Argitaratua: (2019)

Immunogenicity in CAR T cell immunotherapy
nork: Emily Yu
Argitaratua: (2023)

Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
nork: Aman P. Singh, et al.
Argitaratua: (2020)

New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future
nork: Cribioli Elisabetta, et al.
Argitaratua: (2011)

The FDA's Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
nork: Peter Marks
Argitaratua: (2019)

Biomarkers in individualized management of chimeric antigen receptor T cell therapy
nork: Mengyi Du, et al.
Argitaratua: (2020)

Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer
nork: Ilnaz Rahimmanesh, et al.
Argitaratua: (2021)

The EBMT/EHA CAR-T Cell Handbook
Argitaratua: (2022)

The EBMT/EHA CAR-T Cell Handbook
Argitaratua: (2022)

The EBMT/EHA CAR-T Cell Handbook
Argitaratua: (2022)

General and Specific Cytotoxicity of Chimeric Antisense Oligonucleotides in Bacterial Cells and Human Cell Lines
nork: Katya B. Popova, et al.
Argitaratua: (2024)

Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
nork: Zixun Yin, et al.
Argitaratua: (2021)

Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy
nork: Dian Xiong, et al.
Argitaratua: (2024)

Model‐informed drug development of autologous CAR‐T cell therapy: Strategies to optimize CAR‐T cell exposure leveraging cell kinetic/dynamic modeling
nork: Anna M. Mc Laughlin, et al.
Argitaratua: (2023)

Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment
nork: Xuejia Kang, et al.
Argitaratua: (2024)

Chimeric antigen receptor engineered cells and their clinical application in infectious disease
nork: Chen Qian, et al.
Argitaratua: (2022)

Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T‐Cell Therapy
nork: Deni Hardiansyah, et al.
Argitaratua: (2019)

PSCA is a target of chimeric antigen receptor T cells in gastric cancer
nork: Di Wu, et al.
Argitaratua: (2020)

Circulating maternal chimeric cells have an impact on the outcome of biliary atresia
nork: Ryuta Masuya, et al.
Argitaratua: (2022)